MXCT
NASDAQ
$1.23
MaxCyte Inc (MXCT)
MaxCyte Inc. (MXCT) is a pioneering company in cell-engineering, known for its proprietary Flow Electroporation® technology that facilitates the efficient and scalable delivery of nucleic acids and proteins across various cell types. Serving a diverse and prestigious clientele, including leading biopharmaceutical firms and renowned research institutions, MaxCyte is strategically positioned to leverage the burgeoning cell and gene therapy market. The company's advanced platforms are integral to the development of innovative cell-based therapies and vaccines, thus addressing the rising global demand for transformative medical solutions. With a strong commitment to healthcare advancements, MaxCyte is well-equipped to enhance patient outcomes while seizing significant market opportunities.
Sector:
Healthcare
Industry:
Medical Devices
Buy
Target: $4.11 (+233.90%)
Market Cap
$116M
P/B Ratio
0.74
Free Cash Flow Yield
-25.37%
Beta (5Y)
1.28
Price Chart
Valuation
Market Cap$116M
P/S3.88
P/B0.74
Profitability
Total Revenue (TTM)$20M
Gross Profit (TTM)$26M
EBITDA-$41M
Profit Margin-121.2%
Operating Margin-64.1%
EPS-$0.37
Financial Health
Free Cash Flow Yield-25.37%
Growth & Risk
EPS 5Y CAGR+12.02%
Revenue 5Y CAGR+0.02%
Beta (5Y)1.28
Sharpe Ratio-0.57